AbbVie Inc.(ABBV) Stock Research - Grey Stern Research

AbbVie Inc. (ABBV) Stock Analysis

$185.16 (1.64%)

ABBV Financial Performance


Use the table below to view AbbVie Inc.'s financial profile. This data is gathers from the latest available financial statements. Annual data is taken from the trailing 12 months of statements. All numbers are reported in US Dollars and so any foreign currencies are converted to USD so comparison's can be done.

Based on Financial Statements from Q1 - 2024

Metric Value Ranking among Peers
Price $182.17 -
52 Week Low $135.85 -
52 Week High $186.11 -
Market Cap $321.7 Billion 3/8
Gross Margin 67% 7/8
Profit Margin 11% 5/8
EBITDA margin 41% 3/8
Q1 - 2024 Revenue $12.3 Billion 4/8
Q1 - 2024 Earnings $1.4 Billion 5/8
Q1 - 2024 Free Cash Flow $3.8 Billion 1/8
Trailing 4 Quarters Revenue $54.4 Billion 4/8
Trailing 4 Quarters Earnings $6.0 Billion 3/8
Quarterly Earnings Growth 473% 2/8
Annual Earnings Growth -22% 3/8
Quarterly Revenue Growth 1% 6/8
Annual Revenue Growth -6% 6/8
Cash On Hand $18.1 Billion 2/8
Short Term Debt $10.2 Billion 1/8
Long Term Debt $63.8 Billion 1/8

AbbVie Inc. Financial Metrics


Financial metrics are a set of useful numbers that can give key performance indicators of a company. The various metrics can include information about profitability, growth, and debt load. When combined and use properly they can tell an analyst a compelling fact-based story of how the company is currently performing. To compare AbbVie Inc.'s metrics versus it's peers make sure to run our peer analysis tool.

Valuation Metrics

Metric Value Ranking among Peers
PE 53.68 4/8
PS 5.91 3/8
PB 39.98 2/8
PC 17.81 6/8
Liabilities to Equity 17.59 1/8
ROA 0.04 3/8
ROE 0.75 1/8
Current Ratio 1.06 7/8
Quick Ratio 0.13 3/8
Long Term Debt to Equity 7.97 2/8
Debt to Equity 9.24 2/8
Burn Rate 4.84 1/8
Cash to Cap 0.06 3/8
CCR 2.81 1/8
EV to EBITDA 74.58 3/8
EV to Revenue 6.94 3/8

Company Details

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

CEO: Mr. Richard Gonzalez

Website: https://www.abbvie.com

Address: 1 N Waukegan Rd North Chicago, ILLINOIS

Exchange: New York Stock Exchange

Industry: Drug Manufacturers—General

AbbVie Inc. Peer Analysis


A useful and more reliable way of seeing the health of a company is to compare it to other companies operating in the same sector. Below is our list of companies which we rank are the closest peers to AbbVie Inc.. If you feel that peers should be added or removed from this list please contact us. To run an in-depth peer analysis which compares many financial metrics click on the link below.

Stock Ticker Market Cap
Pfizer Inc. PFE $174.4 Billion
Bristol-Myers Squibb Company BMY $102.3 Billion
Gilead Sciences, Inc. GILD $95.9 Billion
Merck & Co., Inc. MRK $317.3 Billion
Johnson & Johnson JNJ $386.6 Billion
Amgen Inc. AMGN $179.6 Billion
Eli Lilly and Company LLY $764.7 Billion
Run Peer Analysis
Income Statement
Balance Sheet
Cash Flow Statement
ABBV Income Statements
Quarter Year Revenue Earnings
Q1 2024 $ 12.3 Billion $1.4 Billion
Q4 2023 $ 14.3 Billion $822.0 Million
Q3 2023 $ 13.9 Billion $1.8 Billion
Q2 2023 $ 13.9 Billion $2.0 Billion
Q1 2023 $ 12.2 Billion $239.0 Million
Q4 2022 $ 15.1 Billion $2.5 Billion
Q3 2022 $ 14.8 Billion $3.9 Billion
Q2 2022 $ 14.6 Billion $924.0 Million

View All

ABBV Balance Sheets
Quarter Year Cash & Equivalents Total Assets Total Debt Total Equity
Q1 2024 $18.1 Billion $148.9 Billion $74.0 Billion $8.0 Billion
Q4 2023 $12.8 Billion $134.7 Billion $59.4 Billion $10.4 Billion
Q3 2023 $13.3 Billion $136.2 Billion $60.7 Billion $12.1 Billion
Q2 2023 $9.2 Billion $138.8 Billion $61.0 Billion $12.9 Billion
Q1 2023 $6.7 Billion $134.5 Billion $62.1 Billion $13.3 Billion
Q4 2022 $9.2 Billion $138.8 Billion $63.3 Billion $17.3 Billion
Q3 2022 $11.8 Billion $141.3 Billion $69.6 Billion $16.0 Billion
Q2 2022 $8.5 Billion $143.2 Billion $72.9 Billion $14.7 Billion

View All

ABBV Cash Flow Statements
Quarter Year freeCashFlow capitalExpenditure netChangeInCash
Q1 2024 $3.8 Billion -$193.0 Million $5.3 Billion
Q4 2023 $4.5 Billion -$205.0 Million -$473.0 Million
Q3 2023 $1.8 Billion $0 $1.8 Billion
Q2 2023 $2.0 Billion $0 $2.0 Billion
Q1 2023 $4.0 Billion -$175.0 Million -$2.5 Billion
Q4 2022 $7.2 Billion -$213.0 Million -$2.6 Billion
Q3 2022 $7.4 Billion -$177.0 Million $3.3 Billion
Q2 2022 $4.9 Billion -$143.0 Million $2.4 Billion

View All

Cookies

We use cookies to offer a better browsing experience. Cookies enhance site navigation, analyze site usage, and assist in our marketing efforts. By clicking Accept. you agree to the storing of cookies on your device. To refuse all non-required cookies, click on Decline.

Accept View Terms & Conditions